Recent 8-K filings for OGEN

• May 19, 2026 12:38 UTC other_material materiality 0.75 positive item 7.01item 8.01item 9.01

  Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device

  Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.

• May 07, 2026 23:59 UTC m_and_a materiality 0.65 positive item 8.01item 9.01

  Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI

  LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.

• Apr 13, 2026 23:59 UTC other_material materiality 0.70 positive item 8.01item 9.01

  Oragenics dosed first patient in Phase IIa trial of ONP-002 for mild traumatic brain injury

  First patient dosed at Mackay Hospital (Australia) days after site activation on March 31, 2026.

• Mar 11, 2026 23:59 UTC other_material materiality 0.65 positive item 8.01item 9.01

  Oragenics gets HREC approval, starts Phase IIa site activation for ONP-002 in Australia; explores CNS asset acquisition

  Received final HREC approval in Australia for Phase IIa trial of ONP-002 for concussion/mTBI.

• Nov 12, 2025 23:59 UTC other_material materiality 0.75 positive item 8.01item 9.01

  Oragenics regains NYSE compliance, raises $16.5M, partners with Receptor.AI, advances Phase IIa trial

  Regained NYSE American compliance on Oct 20, 2025, resolving equity deficiency and removing below-compliance indicator.

• Oct 21, 2025 23:59 UTC other_material materiality 0.70 positive item 1.01item 3.01item 7.01item 9.01

  Oragenics settles Ladenburg dispute for $700K; regains NYSE American compliance

  Paid $700K to Ladenburg Thalmann to settle $2.5M fee dispute; mutual release and arbitration dismissal.

• Aug 11, 2025 23:59 UTC other_material materiality 0.60 positive item 8.01item 9.01

  Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025

  Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.

• Jul 02, 2025 23:59 UTC other_material materiality 0.75 neutral item 1.01item 3.03item 5.03item 8.01item 9.01

  Oragenics closes $16.5M public offering of Series H Preferred Stock and Warrants

  Issued 660,000 shares of Series H Convertible Preferred Stock at $25/unit with warrants to buy 660,000 additional shares.

• May 28, 2025 23:59 UTC other_material materiality 0.65 neutral item 3.03item 5.03item 8.01item 9.01

  Oragenics approves 1-for-30 reverse stock split to meet NYSE American listing standards

  Reverse stock split at 1-for-30 ratio; effective 12:01 a.m. ET on June 3, 2025.

• May 02, 2025 23:59 UTC leadership materiality 0.65 neutral item 1.01item 5.02item 5.07item 9.01

  Oragenics appoints Janet Huffman as permanent CEO; shareholders authorize reverse stock split up to 1:50

  Janet Huffman, previously CFO and Interim CEO, appointed permanent CEO effective May 2, 2025 under one-year agreement.

Materiality & sentiment trend

Max materiality 0.75 · Median 0.57 · Most common event other_material

9 positive 0 negative 11 neutral

source · OGEN on sec.gov